A Study of HS248 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is a non-random, open multi-center study This study is a non-random, open
multi-center phase I study, aimed at evaluation period research, aimed at In the evaluation
phase study, it aims to evaluate the safety, tolerance PK characteristics and preliminary
anti-tumor activity of HS248 in patients with advanced solid tumors. The study was divided
into 2 phases, including dose escalation and dose expansion。